Navigation Links
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
Date:11/25/2008

MONTREAL, Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, on December 9, 2008.

The presentation is entitled "Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML". The trial was an open label, multi-center study evaluating the safety and efficacy of AEG35156 in combination with chemotherapy in AML patients in first relapse after a short initial CR or with primary refractory disease. A total of 51 patients were enrolled in the study. The results demonstrate that AEG35156 is well tolerated at 350 mg/m2 in combination with idarubicin and cytarabine. The results also support the finding that AEG35156 combination therapy may induce high response rates in AML patients not responding to frontline induction therapy. Updated results on additional patients will be presented at the ASH Annual Meeting.

The study's principal investigator, Dr. Aaron D. Schimmer, M.D., Ph.D. of the Princess Margaret Hospital in Toronto will present the results of this study at the ASH session entitled "Acute Myeloid Leukemia - Therapy, Excluding Transplantation".

In addition, PD data from the same study will be presented by Dr. Carter Bing of the MD Anderson Cancer Center in a poster on December 7 under the title "Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML".

Details of each of these presentations are listed below.

2008 ASH Annual Meeting ASH - Oral Presentation

Title: Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156)

in Co
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
2. Aegera Therapeutics welcomes two experienced executives to its board of directors
3. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
4. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
5. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
6. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
7. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... FORT LAUDERDALE, Fla. , Sept. 17, 2014 ... signed an agreement to form a Special Purpose Vehicle in ... based Jatropha centric agro energy company. The SPV shall ... U.S. registered entity with AFAI as majority shareholder. The SPV ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 Escape Alert, ... for pets which will alert owners if their pet has ... GPS from an implanted microchip in the pet’s body. This ... microchips for pets have been around for many years, they ... are not able to track a pet’s location or alert the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 The ... committed to lowering the barriers to innovation in ... the appointment of Carmen Nitsche as Executive Director ... to expand its global reach. , Carmen joins ... Vice President, Corporate Development. At Accelrys, she managed ...
Breaking Biology Technology:AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... photonics and renewable energy will be the focus of ... to 14, 2009 at McMaster University in Hamilton, Ontario, ... in conjunction with the event. , The 4th Nano ... the 14th Canadian Semiconductor Technology Conference (CSTC2009) will bring ...
... UC Riverside have made an accidental discovery in ... information in computers can be transported or stored. ... electrons possess that makes them behave like tiny ... of spin-based semiconductor technology such as ultrahigh-speed computers. ...
... programs give sponsors easy-to-use tools to store, mine and ... transfer knowledge base to ensure enrollment success, NEWTON, ... technology leader, announced the release of a new,product, "Center ... in-house recruitment capabilities for clinical,trial sponsors. The goal is ...
Cached Biology Technology:Joint nanotechnology forum to focus on electronics, photonics, renewable energy 2Discovery by UC Riverside physicists could enable development of faster computers 2Discovery by UC Riverside physicists could enable development of faster computers 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 2TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 4
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... Environmental Health at the Mailman School of Public Health ... asthma and prenatal exposure to two phthalates used in ... in the journal Environmental Health Perspectives . ... higher levels of the chemicals, butylbenzyl phthalate (BBzP) and ... percent increase in risk of developing asthma between age ...
(Date:9/16/2014)... CLEVELAND, Ohio (September 17, 2014)The North American Menopause ... for the comprehensive care of midlife womenon everything ... feature, "The North American Menopause Society Recommendations for ... today in the Society,s journal Menopause . ... recommendations for the care of midlife women freely ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... A team of scientists from the University Hospitals of ... bowel diseases have low bone mass and poor bone architecture ... at increased risk of fracture. Inflammatory bowel disease ... inflammation of the bowel. Two of the most common disorders ...
... new study presented today at the World Congress on ... a commonly used injectible contraceptive, is associated with higher ... in combination with estrogens. Depot medroxyprogesterone acetate ... birth control drug which is injected every 3 months. ...
... muscle tissue experiences trauma or disease, such as ... as "satellite cells" respond to repair and regenerate ... neuromuscular diseases, such as muscular dystrophy, which affect ... researchers have used time-lapse photography to document satellite ...
Cached Biology News:Caught on tape: Muscle stem cells captured on video by MU researcher 2
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: